Drug Profile
Research programme: therapeutic agents - Bayer/University of Pittsburgh
Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Bayer; University of Pittsburgh
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Haematological disorders; Lung disorders
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 28 Feb 2021 No recent reports of development identified for research development in Haematological-disorders in USA
- 28 Feb 2021 No recent reports of development identified for research development in Lung-disorders in USA